Adagio Therapeutics (ADGI) – Company Press Releases
-
Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference
-
Invivyd Announces Changes to Executive Team
-
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
-
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
-
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
-
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
-
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
-
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
-
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
-
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
-
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
-
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
-
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
-
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
-
Adagio Therapeutics Announces Corporate Name Change to Invivyd
-
Adagio Therapeutics to Participate in Upcoming Investor Conferences
-
Adagio Therapeutics to Participate in Upcoming Investor Conferences
-
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
-
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
-
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign
-
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
-
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
-
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
-
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
-
Adagio Therapeutics Reports First Quarter 2022 Financial Results
-
Adagio Therapeutics Reports First Quarter 2022 Financial Results
-
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
-
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
-
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for
-
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for
-
Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
-
Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
-
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
-
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
-
Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
-
Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
-
Adagio Therapeutics Announces CEO Succession Plan
-
Adagio Therapeutics Announces CEO Succession Plan
-
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
-
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
-
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
-
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
-
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
-
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
-
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
-
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19
-
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19
-
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
Back to ADGI Stock Lookup
